- Home
- VERO vs SCNI Comparison
VERO vs SCNI Comparison
Compare VERO & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- SCNI
- Stock Information
- Founded
- VERO N/A
- SCNI 2003
- Country
- VERO Canada
- SCNI Israel
- Employees
- VERO N/A
- SCNI N/A
- Industry
- VERO Medical/Dental Instruments
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERO Health Care
- SCNI Health Care
- Exchange
- VERO Nasdaq
- SCNI Nasdaq
- Market Cap
- VERO 2.2M
- SCNI 1.9M
- IPO Year
- VERO N/A
- SCNI N/A
- Fundamental
- Price
- VERO $3.18
- SCNI $2.55
- Analyst Decision
- VERO
- SCNI
- Analyst Count
- VERO 0
- SCNI 0
- Target Price
- VERO N/A
- SCNI N/A
- AVG Volume (30 Days)
- VERO 3.1M
- SCNI 1.1M
- Earning Date
- VERO 05-15-2025
- SCNI 07-01-2025
- Dividend Yield
- VERO N/A
- SCNI N/A
- EPS Growth
- VERO N/A
- SCNI N/A
- EPS
- VERO N/A
- SCNI N/A
- Revenue
- VERO $60,997,000.00
- SCNI $658,000.00
- Revenue This Year
- VERO N/A
- SCNI N/A
- Revenue Next Year
- VERO $7.47
- SCNI N/A
- P/E Ratio
- VERO N/A
- SCNI N/A
- Revenue Growth
- VERO N/A
- SCNI N/A
- 52 Week Low
- VERO $2.10
- SCNI $1.90
- 52 Week High
- VERO $17.49
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- VERO 65.91
- SCNI 46.70
- Support Level
- VERO $2.31
- SCNI $2.32
- Resistance Level
- VERO $2.49
- SCNI $6.18
- Average True Range (ATR)
- VERO 0.24
- SCNI 0.41
- MACD
- VERO 0.09
- SCNI -0.01
- Stochastic Oscillator
- VERO 50.00
- SCNI 8.10
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.